echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Anstelai obtains the exclusive right to sell the antiallergic drug ALOC in China

    Anstelai obtains the exclusive right to sell the antiallergic drug ALOC in China

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Astaire Pharmaceutical (China) Co., Ltd

    announced in Beijing on January 16 that Astaire China and Xiehe fermentation Kirin Co., Ltd

    officially signed an agreement

    Astaire China has obtained the exclusive right to sell the antiallergic drug alopec (chemical name: orotadine hydrochloride) in China since January 1, 2014

    Alopec, independently developed by kylin, is a new type of antihistamine drug

    It is the first anti allergic drug approved in Japan for the treatment of erythema multiforme exudative

    It was marketed in China in 2011 with 5mg tablets and approved in China for the treatment of allergic rhinitis, urticaria and pruritus (eczema, dermatitis, pruritus, pruritus, psoriasis vulgaris and pleomorphism) Exudative erythema)

    For this cooperation, Mr

    Heitian Changli, general manager of anstar China, has great expectations

    He believes that with the focus and experience of anstar China in the field of Dermatology, he is confident to bring aloche, a new oral anti allergy preparation, to more patients in need, and help them to alleviate the problems of allergic skin diseases and return to normal life and work as soon as possible

    Based on the requirements of the framework agreement, after obtaining the sub packaging license, Ansteel China will start the sales of ALOC in the Chinese market

    Anstelai Pharmaceutical Group is a R & D-oriented enterprise which is headquartered in Tokyo, Japan and develops, produces and sells innovative pharmaceutical products worldwide

    Astaire China is a wholly-owned subsidiary of its investment in China

    With the outstanding performance of the immunosuppressant Proctor, BPH and OAB, anstar has been the world leader in transplantation and urology.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.